The U.S. Digital Therapeutics market size was valued at US$ 1.50 billion in 2021 and is expected to hit US$ 11.2 billion by 2030, growing at a compound annual growth rate (CAGR) of 24.10% from 2022 to 2030.
The U.S. Digital Therapeutics market size was valued at US$ 1.50 billion in 2021 and is expected to hit US$ 11.2 billion by 2030, growing at a compound annual growth rate (CAGR) of 24.10% from 2022 to 2030.
Growth Factors:
The continuously changing digital landscape, rising consumerism in healthcare, the COVID-19 pandemic, and initiatives by key companies are some of the key factors fueling the market growth. In October 2021, Click Therapeutics, Inc. received USD 52 million in Series B funding from multiple investors. This enabled the development and commercialization of the company’s prescription digital therapeutic pipeline, while also helping the company advance its platform capabilities.
Full Report is Ready | Request Sample of This Report@ https://www.novaoneadvisor.com/report/sample/6591
Technological advancements aiming to provide transformational healthcare solutions are further anticipated to assist the market growth in the near future. In June 2020, ATAI Life Sciences, in an attempt to enter the digital therapeutics space, launched the IntroSpect Digital Therapeutics platform. The company will provide DTx and precision psychiatry solutions in a probe to combat burgeoning mental health disorders.
The increasing number of smartphone users in the U.S. is another key factor driving the market growth. Awareness of smart health tracking is also expected to increase in the country due to the rapid proliferation of smart healthcare devices. Digital therapeutics can offer on-demand care to patients, with the ability to diagnose and treat patients earlier. Moreover, biopharmaceutical companies are collaborating with digital therapeutic providers to give patients a better quality of care, thereby propelling growth.
Despite the advantages of DTx services and a large smartphone user base in the U.S., it never experienced mass consumer adoption before the COVID-19 outbreak. The pandemic created a major growth opportunity for this technology. CMS and FDA have already mentioned the vital nature of virtual care services in the overall COVID-19 response strategy.
Social distancing and self-isolation have resulted in increased anxiety & stress. According to Mental Health America, there was nearly a 19% increase in clinical anxiety in the first week of February 2020, and around a 12% increase in the first two weeks of March. DTx therapies can help manage these conditions and provide evidence-based solutions. Companies such as BigHealth, Happify, Palo Alto Health Science, and Pear Therapeutics are constantly trying to increase their consumer base and reach out to more patients during this pandemic.
Report Scope of the U.S. Digital Therapeutics Market
| Report Coverage | Details |
| Market Size in 2021 | USD 1.50 Billion |
| Revenue Projection By 2030 | USD 11.2 Billion |
| Growth Rate | CAGR of 24.10% from 2022 to 2030 |
| Base Year | 2021 |
| Historical data | 2017 - 2020 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Application, end use |
| Companies Mentioned | Omada Health Inc.; Teladoc Health, Inc.; 2Morrow Inc.; Propeller Health (ResMed); Fitbit Health Solutions; Canary Health; WellDoc, Inc.; Noom, Inc.; Pear Therapeutics, Inc.; Click Therapeutics, Inc.; Akili Interactive Labs, Inc.; Better Therapeutics, Inc |
Application Insights
Diabetes dominated the application segment in 2021 with more than 27% of the revenue share. Diabetes prevalence is growing rapidly and is linked to blindness, heart attack, kidney failure, stroke, and gangrene in severe cases. Digital therapeutics are being used for the management & prevention of diseases by helping patients change their behavior through constant monitoring, thus improving their health in the long run.
Based on application, the U.S. digital therapeutics market is segmented into diabetes, obesity, CVD, respiratory diseases, smoking cessation, CNS diseases, and others. The CNS diseases segment is expected to show significant growth during the forecast period, owing to the increasing incidence of neurological diseases in the U.S. Alzheimer’s disease, expressive aphasia, degenerative diseases, Huntington’s disease, multiple sclerosis, and Parkinson’s disease are some of the most common neurological diseases that affect a growing proportion of the U.S. population.
Several digital therapeutics companies have been catering to the specific needs of Central Nervous System (CNS) disease patients to reduce anxiety and keep track of their daily activities. The demand has increased after the nationwide lockdown brought on by the COVID-19 pandemic.
According to a KFF tracking poll, around 47% of Americans staying at home have reported negative mental health effects as of March 2020. Out of them, over 21% have reported a major negative impact on their mental health. The FDA has released new guidelines for the computerized behavioral therapy and other DTx solutions during this public health emergency, which is expected to fuel the growth.
Full Report is Ready |Quick Buy This Premium Report From Here: https://www.novaoneadvisor.com/report/checkout/6591
End-use Insights
The patient end-user segment dominated the overall market with more than 32% of the revenue share in 2021. The increased adoption of these tools can be attributed to their added benefits, one of which is effective health management at an affordable cost. In addition, the presence of advanced healthcare IT solutions and supportive government programs in the country are factors expected to further boost the adoption of digital therapeutics by patients.
Based on end-use, the market is segmented into patients, providers, payers, employers, & other end-users. The employer segment is expected to show notable growth during the forecast period. Employers are focusing on the management of employee healthcare costs, which is expected to drive segment growth. Moreover, growing awareness through employee healthcare programs is expected to propel the adoption of digital therapeutics for maintaining employee wellbeing.
The availability of various mHealth apps, such as Vida Health, used by payers, providers, and employers to monitor chronic conditions such as prediabetes, obesity, hypertension, & mental health issues, is another factor expected to propel market growth.
Some of the prominent players in the U.S. Digital Therapeutics market include:
- Omada Health Inc.
- Teladoc Health, Inc.
- 2Morrow Inc.
- Propeller Health (ResMed)
- Fitbit Health Solutions
- Canary Health
- WellDoc, Inc.
- Noom, Inc.
- Pear Therapeutics, Inc.
- Click Therapeutics, Inc.
- Akili Interactive Labs, Inc.
- Better Therapeutics, Inc.
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at U.S. for the period of 2017 to 2030
- By Application
- Diabetes
- Obesity
- CVD
- Respiratory Diseases
- Smoking Cessation
- CNS Disease
- Others
- By End-use
- Patients
- Providers
- Payers
- Employers
- Others
Click Here to View Full Report Table of Contents
Key Questions Answered in U.S. Digital Therapeutics Market Report
What will be the sales/revenue generated by U.S. Digital Therapeutics across all regions during the forecast period?
What are the opportunities in the U.S. Digital Therapeutics market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which application is expected to generate the highest revenue U.S. in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
What is the market position of different companies operating in the U.S. market?
Full Report is Ready |Quick Buy This Premium Report From Here: https://www.novaoneadvisor.com/report/checkout/6591
You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333
About Us
Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.
We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. We endeavor to give our clients latest insights on upcoming technologies, new developing markets, dynamically changing business conditions and most recent business-driven applications. These insights help our clients to take informed decisions for their business growth.
For Latest Update Follow Us:
https://www.linkedin.com/company/nova-one-advisor